Bob Nelsen - Arch Venture Partners
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners.
Mr. Nelsen joined ARCH at its founding and has played a significant role in the early sourcing, financing and development of more than thirty companies including nine which have reached valuations exceeding $1 billion. These include Sapphire Energy, the leading algae biofuels producer; Illumina, (ILMN) the world-leader in genetic analysis; Ikaria, a leader in infant critical care, Everyday Learning Corporation (publisher of the leading K-6 math curriculum in the U.S.); Aviron (AVIR, acquired by Medimmune-MEDI), which produced the first nasal flu vaccine; NetBot, the first online shopping agent; R2 Technology (acquired by Hologic-HOLX), the standard of care in computer-aided breast cancer detection, Alnylam Pharmaceuticals (ALNY), XenoPort (XNPT), Caliper Life Sciences (CALP), Trubion Pharmaceuticals (TRBN), Adolor (ADLR), Array BioPharma (ARRY), deCODE Genetics (DCGN), Nanosys, GenVec (GNVC), IDUN Pharmaceuticals (acquired by Pfizer-PFE), Genomica (GNOM, acquired by Exelixis-EXEL), Surface Logix, NeurogesX (NGSX), Classmates.com (acquired by United Online-UNTD), Nura (acquired by Omeros), Kythera Biopharmaceuticals, Elixir Pharmaceuticals, Theraclone Sciences, VLST, Ensemble Discovery, Accelerator, Receptos, Fate Therapeutics, and Agios Pharmaceuticals.
Mr. Nelsen is a director of Sapphire Energy, Ikaria, Fate Therapeutics, Agios Pharmaceuticals, Ensemble Discovery Corp., NeurogesX, and Kythera Biopharmaceuticals. He previously served on the boards of Trubion Pharmaceuticals, Surface Logix, Adolor, NetBot, Everyday Learning, Theraclone, Array BioPharma, Caliper Life Sciences, Illumina, R2 Technology, and Classmates.com, among others. He also serves as a director of the Fred Hutchinson Cancer Research Center. Mr. Nelsen holds an M.B.A. from The University of Chicago and a B.S. in Economics and Biology from the University of Puget Sound.